<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180335</url>
  </required_header>
  <id_info>
    <org_study_id>CSET1376</org_study_id>
    <nct_id>NCT01180335</nct_id>
  </id_info>
  <brief_title>Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer</brief_title>
  <acronym>REMAGUS04</acronym>
  <official_title>Randomized Trial Comparing Standard Neoadjuvant Chemotherapy to Genomic Driven Chemotherapy Regimen in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial is comparing a standard neoadjuvant chemotherapy with a genomic driven
      chemotherapy in patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After a core biopsy, each tumor is profiled using Affymetrix U133plus2 gene expression array.
      DLD30 score (Hess, JCO, 2006) and TOP2A expression are quantified. Patients are then either
      treated with 4FEC followed by 4 docetaxel (standard arm) or by a genomic-driven regimen
      (experiemental arm). In the experimental arm, patients with high DLD30 receive 3 months
      weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel,
      patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate based on the histology</measure>
    <time_frame>Tumoral assessment at 4 and 8 cycles</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles FEC followed by 4 cycles docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genomic driven chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>4 cycles FEC followed by 4 cycles docetaxel</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genomic driven chemotherapy</intervention_name>
    <description>High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.</description>
    <arm_group_label>Genomic driven chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Invasive breast cancer not eligible for conservative surgery

          -  Her2 negative

          -  Amount of tumor cells &gt;30% on HES slides

          -  RIN&gt;6 and amount of RNA&gt;1 ug

          -  No metastases

          -  Subject, age &gt; 18 years and &lt;65 years old

          -  Signed written informed consent

          -  PS 0-1

          -  No previous treatment for breast cancer

          -  Adequate organ function

          -  FEVG &gt;50%

        Exclusion Criteria:

          -  In situ carcinoma

          -  Multifocal cancers

          -  Her2+

          -  Presence of metastasis

          -  Genomic testing not feasible because of tumor cells &lt;30%, RIN&lt;6, insufficient amount
             of RNA

          -  Organ dysfunction that contraindicates chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence LEREBOURS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Ren√© Huguenin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Yves PIERGA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <name_title>ANDRE Fabrice</name_title>
    <organization>G.I.E. REMAGUS</organization>
  </responsible_party>
  <keyword>Genomic driven chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

